Transjugular Intrahepatic Portosystemic Shunt (TIPS): Pathophysiologic Basics, Actual Indications and Results with Review of the Literature

Abstract

Background Transjugular intrahepatic portosystemic shunt (TIPS) is a non-selective portosystemic shunt created using endovascular techniques. During recent years technical improvements and new insights into pathophysiology have modified indications for TIPS placement. In this article we therefore want to discuss current knowledge.

Method A literature review was performed to review and discuss the pathophysiology, indications and results of the TIPS procedure.

Results Established TIPS indications are persistent bleeding despite combined pharmacological and endoscopic therapy and rebleeding during the first five days. A new indication in the European recommendations is early TIPS placement within 72 hours, ideally within 24 hours, in patients bleeding from esophageal or gastroesophageal varices at high risk for treatment failure (e. g. Child-Pugh class C < 14 points or Child-Pugh class B with active bleeding) after initial pharmacological and endoscopic therapy. For prevention of recurrent variceal hemorrhage in the recommendations, covered TIPS placement is the treatment of choice only after failed first-line therapy, although numerous TIPS studies show a prolonged time to rebleeding and a reduction of mortality. Similarly for secondary prophylaxis in patients with refractory ascites, covered TIPS placement may be considered only if the patient continues to be intolerant to NSBBs and is an appropriate TIPS candidate even though studies show that the TIPS procedure controls ascites, improves survival and renal function better than paracentesis. Potential indications for TIPS implantation are Budd-Chiari syndrome, acute portal vein thromboses, hydrothorax, hepatopulmonary and hepatorenal syndrome (Typ 2), portal hypertensive gastropathy (PHG) and prophylaxis of complications of abdominal surgery, very rarely bleeding in ectopic varices or in patients with chylothorax or chylous ascites.

Conclusion TIPS placement is an established procedure with a new indication as “early TIPS”. In the European recommendations it is only the second-line therapy for prevention of recurrent variceal hemorrhage and for secondary prophylaxis in patients with refractory ascites although several studies showed a clear benefit of the TIPS procedure compared to ligation and NSBBs.

Key Points 

• In addition to already established indications, new European recommendations suggest early TIPS placement in patients bleeding from esophageal or gastroesophageal varices at high risk for treatment failure.

Citation Format

• Strunk H, Marinova M, . Transjugular Intrahepatic Portosystemic Shunt (TIPS): Pathophysiologic Basics, Actual Indications and Results with Review of the Literature. Fortschr Röntgenstr 2018; 190: 701 – 711

Key words

TIPS - porto-systemic shunt - stent-grafts - esophageal varices - transhepatic - ascites

• References

• 1 Rossle M, Richter GM, Noldge G. et al. New non-operative treatment for variceal haemorrhage.[letter]. Lancet 1989; 2: 153
• 2 Bureau C, Pagan JC, Layrargues GP. et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27: 742-747
• 3 Henderson JM. Surgery versus transjugular intrahepatic portal systemic shunt in the treatment of severe variceal bleeding. Clin Liver Dis 2006; 10: 599-612 , ix
• 4 Rossle M. TIPS: 25 years later. J Hepatol 2013; 59: 1081-1093
• 5 Trebicka J, von Heydebrand M, Lehmann J. et al. Assessment of response to beta-blockers by expression of betaArr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. J Hepatol 2016; 64: 1265-1273
• 6 Villanueva C, Albillos A, Genesca J. et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. Hepatology 2016; 63: 197-206
• 7 Berres ML, Lehmann J, Jansen C. et al. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Liver Int 2016; 36: 386-394
• 8 Allegretti AS, Ortiz G, Cui J. et al. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis 2016; 68: 381-391
• 9 Tan HK, James PD, Sniderman KW. et al. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. J Gastroenterol Hepatol 2015; 30: 389-395
• 10 de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63: 743-752
• 11 Boyer TD, Haskal ZJ. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 2010; 51: 306
• 12 Garcia-Pagan JC, Caca K, Bureau C. et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362: 2370-2379
• 13 Garcia-Pagan JC, Di Pascoli M, Caca K. et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013; 58: 45-50
• 14 Thabut D, Rudler M, Lebrec D. Early TIPS with covered stents in high-risk patients with cirrhosis presenting with variceal bleeding: Are we ready to dive into the deep end of the pool?. J Hepatol 2011; 55: 1148-1149
• 15 Deltenre P, Trepo E, Rudler M. et al. Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding: a systematic review and meta-analysis of controlled trials. Eur J Gastroenterol Hepatol 2015; 27: e1-e9
• 16 Hernández-Gea V, Bureau C. Practice makes better: TIPS procedures in referral centers [editorial]. Hepatology 2017; 67: 473-475
• 17 Sauerbruch T, Mengel M, Dollinger M. et al. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. Gastroenterology 2015; 149: 660-668 .e1
• 18 Salerno F, Camma C, Enea M. et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-834
• 19 Garcia-Pagan JC, Heydtmann M, Raffa S. et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135: 808-815
• 20 Rossle M, Grandt D. TIPS: an update. Best Pract Res Clin Gastroenterol 2004; 18: 99-123
• 21 Kori I, Bar-Zohar D, Carmiel-Haggai M. et al. Budd-Chiari syndrome and acute portal vein thrombosis: management by a transjugular intrahepatic portosystemic shunt (TIPS) and portal vein interventions via a TIPS. J Gastrointest Surg 2006; 10: 417-421
• 22 Ferro C, Rossi UG, Bovio G. et al. Transjugular intrahepatic portosystemic shunt, mechanical aspiration thrombectomy, and direct thrombolysis in the treatment of acute portal and superior mesenteric vein thrombosis. Cardiovasc Intervent Radiol 2007; 30: 1070-1074
• 23 Brensing KA, Textor J, Perz J. et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-295
• 24 Tsauo J, Weng N, Ma H. et al. Role of Transjugular Intrahepatic Portosystemic Shunts in the Management of Hepatopulmonary Syndrome: A Systemic Literature Review. J Vasc Interv Radiol 2015; 26: 1266-1271
• 25 Tsauo J, Shin JH, Han K. et al. Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Chylothorax and Chylous Ascites in Cirrhosis: A Case Report and Systematic Review of the Literature. J Vasc Interv Radiol 2016; 27: 112-116
• 26 Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003; 124: 1700-1710
• 27 Clark TW. Stepwise placement of a transjugular intrahepatic portosystemic shunt endograft. Tech Vasc Interv Radiol 2008; 11: 208-211
• 28 Fidelman N, Kwan SW, LaBerge JM. et al. The transjugular intrahepatic portosystemic shunt: an update. Am J Roentgenol 2012; 199: 746-755
• 29 Boyvat F, Aytekin C, Harman A. et al. Transjugular intrahepatic portosystemic shunt creation in Budd-Chiari syndrome: percutaneous ultrasound-guided direct simultaneous puncture of the portal vein and vena cava. Cardiovasc Intervent Radiol 2006; 29: 857-861
• 30 Boyvat F, Harman A, Ozyer U. et al. Percutaneous sonographic guidance for TIPS in Budd-Chiari syndrome: direct simultaneous puncture of the portal vein and inferior vena cava. Am J Roentgenol 2008; 191: 560-564
• 31 Chen S, Li X, Wei B. et al. Recurrent variceal bleeding and shunt patency: prospective randomized controlled trial of transjugular intrahepatic portosystemic shunt alone or combined with coronary vein embolization. Radiology 2013; 268: 900-906
• 32 Lakhoo J, Bui JT, Zivin SP. et al. Root Cause Analysis of Rebleeding Events following Transjugular Intrahepatic Portosystemic Shunt Creation for Variceal Hemorrhage. J Vasc Interv Radiol 2015; 26: 1444-1453
• 33 Blue RC, Lo GC, Kim E. et al. Transjugular Intrahepatic Portosystemic Shunt Flow Reduction with Adjustable Polytetrafluoroethylene-Covered Balloon-Expandable Stents Using the “Sheath Control” Technique. Cardiovasc Intervent Radiol 2016; 39: 935-939
• 34 Rossi P, Salvatori FM, Fanelli F. et al. Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology 2004; 231: 820-830
• 35 Yang Z, Han G, Wu Q. et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1718-1725
• 36 Perarnau JM, Le Gouge A, Nicolas C. et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol 2014; 60: 962-968
• 37 Pan JJ, Chen C, Caridi JG. et al. Factors predicting survival after transjugular intrahepatic portosystemic shunt creation: 15 years’ experience from a single tertiary medical center. J Vasc Interv Radiol 2008; 19: 1576-1581
• 38 Brensing KA, Horsch M, Textor J. et al. Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic portosystemic stent-shunt. Scand J Gastroenterol 2002; 37: 1070-1076
• 39 Tzeng WS, Wu RH, Lin CY. et al. Prediction of mortality after emergent transjugular intrahepatic portosystemic shunt placement: use of APACHE II, Child-Pugh and MELD scores in Asian patients with refractory variceal hemorrhage. Korean J Radiol 2009; 10: 481-489
• 40 Harrod-Kim P, Saad WE, Waldman D. Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites. J Vasc Interv Radiol 2006; 17: 1605-1610
• 41 Ferral H, Vasan R, Speeg KV. et al. Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures. J Vasc Interv Radiol 2002; 13: 1103-1108
• 42 Schepke M, Roth F, Fimmers R. et al. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol 2003; 98: 1167-1174
• 43 Ripamonti R, Ferral H, Alonzo M. et al. Transjugular intrahepatic portosystemic shunt-related complications and practical solutions. Semin Intervent Radiol 2006; 23: 165-176
• 44 Riggio O, Nardelli S, Moscucci F. et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis 2012; 16: 133-146
• 45 Riggio O, Angeloni S, Salvatori FM. et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 2008; 103: 2738-2746
• 46 Masson S, Mardini HA, Rose JD. et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM 2008; 101: 493-501
• 47 Luca A, Miraglia R, Maruzzelli L. et al. Early Liver Failure after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis with Model for End-Stage Liver Disease Score of 12 or Less: Incidence, Outcome, and Prognostic Factors. Radiology 2016; 280: 622-629
• 48 Wannhoff A, Hippchen T, Weiss CS. et al. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. Aliment Pharmacol Ther 2016; 43: 955-965
• 49 Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L. et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40: 793-801
• 50 Qi X, Tian Y, Zhang W. et al. Covered TIPS for secondary prophylaxis of variceal bleeding in liver cirrhosis: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016; 95: e5680
• 51 Holster IL, Tjwa ET, Moelker A. et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology 2016; 63: 581-589
• 52 Bai M, Qi XS, Yang ZP. et al. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol 2014; 20: 2704-2714
• 53 Bureau C, Thabut D, Oberti F. et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology 2017; 152: 157-163
• 54 Gaba RC, Parvinian A, Casadaban LC. et al. Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis. Clin Radiol 2015; 70: e51-e57